Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
about
Biological activity of lenalidomide and its underlying therapeutic effects in multiple myelomaEctopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cellsImprovement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience.Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaLenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapyOral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.Challenges in multiple myeloma diagnosis and treatment.Salvage therapy of multiple myeloma: the new generation drugs.Carfilzomib in multiple myeloma.Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based PharmacokinetFront-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy.Inhibition of autophagy with clarithromycin: a new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors.Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agentEffect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens.Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study.Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide.A new purpose for an old drug: inhibiting autophagy with clarithromycin.A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.Roxithromycin monotherapy inducing a partial response in a patient with myeloma: a case report.A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma
P2860
Q21285161-9D88117A-A5A2-46D2-8B40-B4D1A4EB2C56Q28542491-28C2ABF8-F727-43CF-9486-AB36330949F5Q34389792-54C0DC33-0C92-45F4-9EC1-39650C3E68EBQ35322473-79D57166-8EEE-4E3B-8FC2-52EDEF409B48Q36012111-6FC809B1-36AF-4812-AB05-C8D9E43993D5Q36104325-84C70051-5053-4564-9524-E0251179ED02Q36524353-44029EBC-2FBE-45D3-A08B-966FFFC42EC4Q36646467-A9A93D86-6BA3-4D68-94AA-08167ED41C3BQ36682832-0E994E60-6695-497C-993A-C9FC615A95B8Q36852225-91303C70-FF3E-41D9-8BC3-104104FC0E52Q38223433-B3BD3BB8-D173-4C51-80AE-4AAE6B00EACCQ38244558-75AF6920-DADE-436E-8AE5-1DEB48F71670Q38372360-B58D0CC8-B61E-49DF-99A6-3E7C6597F177Q38413040-6039DF03-A16F-454B-AAFD-1F8876F89F4CQ38435358-DD06ED04-CA90-4A3C-A6A6-BB18E66D6696Q38882048-4B0A96A9-BC44-496A-867F-8D0CB98020AFQ39172850-954F5C1E-56DD-4B06-A6F0-F228218BD3D1Q39524467-14CF54D3-F850-48F9-ACB3-40A4389A95C5Q40273400-D9EB2DDF-5E6D-4742-8AE4-203A7F081738Q40470311-2B800C48-CCE3-4EDD-A7F3-EFECD182B401Q40817619-95406B9D-585C-40D5-AAB5-65A78634A4A6Q41327770-E96B81C5-D939-44C0-9D8D-12E4D57D5556Q41742650-79FE6E80-0771-40BA-AF40-FED37F7664F1Q45150840-0D3971AB-3489-4252-AD91-27EC41BC0CB1Q45711158-2353DBDE-8A55-413E-A578-D1C7AE28BF20Q48741652-975BC314-BF84-4FAD-8406-518C0F12F373Q49900433-84C5F467-F6B3-41F3-B8DA-B9C7447D9AD4Q55188922-FF533441-3E88-4F81-8AD4-DC10EED78790Q58786182-EB150402-F769-4F32-8CD6-EFE2567CB32E
P2860
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clarithromycin (Biaxin)-lenali ...... ) for newly diagnosed myeloma.
@ast
Clarithromycin (Biaxin)-lenali ...... ) for newly diagnosed myeloma.
@en
type
label
Clarithromycin (Biaxin)-lenali ...... ) for newly diagnosed myeloma.
@ast
Clarithromycin (Biaxin)-lenali ...... ) for newly diagnosed myeloma.
@en
prefLabel
Clarithromycin (Biaxin)-lenali ...... ) for newly diagnosed myeloma.
@ast
Clarithromycin (Biaxin)-lenali ...... ) for newly diagnosed myeloma.
@en
P2093
P2860
P50
P356
P1476
Clarithromycin (Biaxin)-lenali ...... ) for newly diagnosed myeloma.
@en
P2093
A Keith Stewart
David S Jayabalan
Francesca Gay
John A Lust
John Leonard
Morton Coleman
Philip R Greipp
Roger Pearse
Selina Chen-Kiang
Shaji Kumar
P2860
P304
P356
10.1002/AJH.21777
P50
P577
2010-09-01T00:00:00Z